Metabolic profiling in chronic lymphocytic leukemia
Official title: Metabolic Profiling of Leukemic Cells Through Isotope Tracing in Patients With CLL
Run by University of Wisconsin, Madison · NCT04785989 · Data updated 2026-11-12
This study is trying to understand how cancer cells in people with chronic lymphocytic leukemia use different fuels to see if it can help find new ways to treat the disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 16 (estimated) |
| Sponsor | University of Wisconsin, Madison Academic / other |
| Locations | 1 site (Madison, Wisconsin) |
| Status | Recruiting |
| Started | June 13, 2022 |
| Main results expected | October 2026 |
| Study ends | October 2026 |
| Registry record updated | November 26, 2025 |
| Trial ID | NCT04785989 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with a diagnosis of chronic lymphocytic leukemia, either with low or high disease burden, who are treatment-naïve.
✕Probably not a fit
Patients with a history of diabetes or those on carbohydrate-restricting diets may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to investigate the metabolic characteristics of chronic lymphocytic leukemia (CLL) by analyzing the fuel preferences and metabolic dependencies of leukemic lymphocytes. Utilizing a 'top-down' approach, the study will employ metabolic tracing techniques with isotopically labeled glucose and glutamine to uncover metabolic vulnerabilities in CLL. The goal is to fill the existing knowledge gap regarding cancer cell metabolism in the human body, which could lead to new therapeutic targets for treatment. Participants will include adults with varying stages of CLL, both treatment-naïve and with specific disease burdens.
Why it matters
Potential benefit: If successful, this study could identify new metabolic targets for treating chronic lymphocytic leukemia, potentially leading to more effective therapies.
How similar studies have gone: While metabolic profiling in cancer is an emerging field, this specific approach to studying CLL metabolism is novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Group A * Adult (18 years of age or older) * No previous history of cancer * Routine history of normal blood counts and vital signs * Documented Informed Consent Group B * Adult (18 years of age or older) * Diagnosis of CLL with low disease burden defined as Rai stage 0 ((Lymphocytosis; no enlargement of the lymph nodes, spleen, or liver; red blood cell and platelet counts are near normal.) * Treatment naïve * Documented Informed Consent Group C * Adult (18 years of age or older) * Diagnosis of CLL with high systemic disease burden defined as infiltration of bone marrow causing cytopenia * Treatment naïve * Able/willing to have bone marrow aspiration * Documented Informed Consent Exclusion Criteria: For all participants * Prisoners * Psychiatric inpatients or people who are institutionalized * Minor (Less than 18 years of age) * History of diabetes * Cannot be on antihyperglycemic therapy * Carbohydrate restricting diets: Atkins, Vegan, Ketogenic, etc. * Females of child bearing potential * Persons without decision-making capacity * Person who cannot read/write English * Not meeting inclusion criteria defined above
Where it's running
-
University of Wisconsin
Madison, Wisconsin, United States Recruiting
Study contacts
- Principal investigator: Christopher Fletcher, MD — School of Medicine and Public Health, University of Wisconsin, Madison
- Study coordinator: Cancer Connect
- Email: clinicaltrials@cancer.wisc.edu
- Phone: 800-622-8922
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia
This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.
-
Venetoclax plus Zanubrutinib for CLL/SLL in frontline or previously treated patients
This phase II trial tests if venetoclax plus zanubrutinib can safely and effectively treat adults with chronic lymphocytic leukemia or small lymphocytic lymphoma, including those who are newly diagnosed and those who have had prior therapy.
-
Tafasitamab plus Acalabrutinib and Venetoclax for newly treated CLL/SLL
This phase II study tests a combination of tafasitamab, acalabrutinib, and venetoclax in adults who are newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma to see if it is safe and effective.
-
Nemtabrutinib and venetoclax in untreated CLL/SLL
This phase 2 study tests whether combining nemtabrutinib with venetoclax can help people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
-
NX-5948 plus other medicines for B-cell cancers
This trial tests NX-5948 in combination with venetoclax, with or without anti-CD20 antibodies, for adults with CLL/SLL or B-cell lymphoma that has returned or worsened or is newly diagnosed but needing treatment.
-
NX-5948 vs Pirtobrutinib in R/R CLL/SLL
This study tests NX-5948 against pirtobrutinib in people with relapsed or refractory CLL/SLL who have previously tried a covalent BTK inhibitor.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.